Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Share-based Compensation (2016 - 2025)

Aptevo Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $80000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 46.31% year-over-year to $80000.0; the TTM value through Sep 2025 reached $69000.0, down 95.4%, while the annual FY2024 figure was $1.1 million, 51.25% down from the prior year.
  • Share-based Compensation for Q3 2025 was $80000.0 at Aptevo Therapeutics, up from -$160000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $915000.0 in Q1 2023 and bottomed at -$160000.0 in Q2 2025.
  • The 5-year median for Share-based Compensation is $358000.0 (2023), against an average of $360421.1.
  • The largest annual shift saw Share-based Compensation skyrocketed 100.56% in 2022 before it plummeted 158.61% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $178000.0 in 2021, then soared by 100.56% to $357000.0 in 2022, then rose by 0.28% to $358000.0 in 2023, then tumbled by 108.66% to -$31000.0 in 2024, then soared by 358.06% to $80000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Share-based Compensation are $80000.0 (Q3 2025), -$160000.0 (Q2 2025), and $180000.0 (Q1 2025).